Whalesbook
Orchid Pharma's Q3 FY26: Profit Plummets, Audit Concerns Mount
Orchid Pharma Limited has revealed a deeply concerning financial performance for the quarter and nine months ended December 31, 2025. The company reported a consolidated revenue of ₹20,726.70 lakhs for Q3 FY26, marking a 4.8% decline from ₹21,734.25 lakhs in the same period last year.
📉 The Financial Deep Dive
More alarmingly, the company's bottom line has deteriorated significantly. Orchid Pharma posted a consolidated net loss of ₹1,261.35 lakhs for Q3 FY26, a sharp reversal from a profit of ₹2,077.51 lakhs in Q3 FY25. For the nine-month period, the consolidated net loss stands at ₹323.32 lakhs, a substantial drop from a profit of ₹7,736.22 lakhs in the prior year.
On a standalone basis, the situation is equally grim, with a Q3 FY26 net loss of ₹582.43 lakhs (versus a profit of ₹2,390.63 lakhs) and a nine-month standalone net loss of ₹1,460.42 lakhs (versus a profit of ₹7,863.47 lakhs).
An exceptional item of ₹711.27 lakhs was recognized, attributed to employee benefits arising from the implementation of new Labour Codes under IND AS 19.
🚩 Risks & Outlook
The most significant red flag in these results is the qualified conclusion issued by statutory auditors, Singhi & Co., on the consolidated financial statements. The auditors highlighted their reliance on unaudited financial information of subsidiaries and a limited review scope for certain entities, explicitly noting this is a "recurring issue noted in previous periods." This raises serious questions about the transparency and reliability of the company's financial reporting, particularly concerning its subsidiaries.
Adding to the strategic complexity, Orchid Pharma is proceeding with the amalgamation scheme of its holding company, Dhanuka Laboratories Limited, with the next hearing at the National Company Law Tribunal (NCLT) scheduled for March 02, 2026. While proceeds from a Qualified Placement (QIP) in June 2023 have been utilized for subsidiary investment, debt repayment, and capital expenditure, the fundamental financial performance and audit concerns overshadow these developments.
Investors should closely monitor the company's ability to address the auditor's concerns, particularly the recurring issues with subsidiary financials. The continued decline in revenue and widening losses present significant operational challenges. The amalgamation process introduces further uncertainty. The outlook remains challenging without clear remediation steps for the audit qualifications and a reversal in financial performance.